Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Liver Fibrosis, Hepatic Cirrhosis

In brief

The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.

Key facts

Study ID
NCT07610837
Run by
AstraZeneca
People needed
104
Starts
2026-05-07
Expected to finish
2027-07-07
Last updated by the study team
2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.